Home » Research » SARC Clinical Trials » COMPLETED Clinical Trials
A phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients with Advanced Sarcomas
TYPE OF SARCOMA: Undifferentiated Pleomorphic Sarcoma and Poorly Differentiated/Dedifferentiated Liposarcoma DRUG: Pembrolizumab ACCRUAL STATUS: Completed
A Phase 2 Study of Linsitinib (OSI-906) in Pediatric and Adult Wild Type Gastrointestinal Stromal Tumors
TYPE OF SARCOMA: Gastrointestinal stromal tumors DRUG: OSI-906 ACCRUAL STATUS: Completed
A Randomized Phase 3, Multicenter, Open-Label Study Comparing TH-302 in Combination With Doxorubicin vs. Doxorubicin Alone in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
TYPE OF SARCOMA: Locally advanced or metastatic soft tissue sarcomaDRUG: TH-302 combined with doxorubicin vs. doxorubicin aloneACCRUAL STATUS: Completed
Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma
TYPE OF SARCOMA: Advanced or Metastatic Untreated Soft Tissue SarcomaDRUG: Trabectedin Infused to DoxorubicinACCRUAL STATUS: Terminated
Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients
TYPE OF SARCOMA: Metastatic GIST DRUG: Imatinib ACCRUAL STATUS: Terminated
SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma
TYPE OF SARCOMA: Metastatic Leiomyosarcoma DRUG: Mocetinostat & Gemcitabine ACCRUAL STATUS: Completed
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
TYPE OF SARCOMA: Ewing’s sarcoma, osteosarcoma, synovial sarcoma, rhabdomyosarcoma, alveolar soft part sarcoma, desmoplastic small round cell tumor, extraskeletal myxoid chondrosarcoma, clear cell sarcomaDRUG: R1507ACCRUAL STATUS: Completed
Trial of Dasatinib in Advanced Sarcomas
TYPE OF SARCOMA: Leiomyosarcoma, liposarcoma, MFH/pleomorphic undifferentiated sarcoma, rhabdomyosarcoma, malignant peripheral nerve sheath tumor, osteosarcoma (skeletal or extraosseous), chondrosarcoma, ewing’s, alveolar soft part sarcoma, chordoma, epithelioid sarcoma, giant cell tumor of bone, hemangiopericytoma/solitary fibrous tumor, gastrointestinal stromal tumors (GIST) DRUG: Dasatinib ACCRUAL STATUS: Completed
A Trial of Perifosine in Patients With Chemo-Insensitive Sarcomas
TYPE OF SARCOMA: Chondrosarcoma, extra-skeletal myxoid chondrosarcoma or alveolar soft part sarcomaDRUG: PerifosineACCRUAL STATUS: Completed
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors
TYPE OF SARCOMA: Malignant peripheral nerve sheath tumors sporadic or NF1 associated DRUG: Adriamycin/ifosfamide and Adriamycin/etoposide ACCRUAL STATUS: Completed
Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma
TYPE OF SARCOMA: Uterine Leiomyosarcoma DRUG: Gemcitabine and Docetaxel ACCRUAL STATUS: Completed
Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans
TYPE OF SARCOMA: Dermatofirbrosarcoma Protuberans DRUG: Gleevec (Imatinib Mesylate) ACCRUAL STATUS: Completed
Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing’s Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma
TYPE OF SARCOMA: Recurrent Ewing’s Sarcoma, Osteosarcoma, or Unresectable or Locally Recurrent ChondrosarcomaDRUG: Gemcitabine and DocetaxelACCRUAL STATUS: Completed
Comparison of Gemcitabine v. Gemcitabine Plus Docetaxel in Unresectable Soft Tissue Sarcoma
TYPE OF SARCOMA: Unresectable soft tissue sarcoma DRUG: Gemcitabine and Docetaxel ACCRUAL STATUS: Completed
Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma
TYPE OF SARCOMA: Ewing’s Family (including PNET), OsteosarcomaSynovial Sarcoma, Leiomyosarcoma, Rhabdomyosarcoma (including alveolar, embryonal and pleomorphic), Liposarcoma (all variants), Malignant Fibrous Histiocytoma, Peripheral Nerve Sheath (including MPNST, neurofibrosarcoma, schwannoma), Fibrosarcoma, Angiosarcoma (all variants), Desmoid Tumor, GI Stromal (c-kit negative only) DRUG: Imatinib Mesylate (Gleevec) ACCRUAL STATUS: Completed
ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide or Irinotecan in Patients With Previously Treated, Incurable Ewing Sarcoma
TYPE OF SARCOMA: Ewing Sarcoma DRUG: Niraparib, Temozolomide and Irinotecan ACCRUAL STATUS: Not Recruiting
© 2023 Sarcoma Alliance For Research Through Collaboration
Sign up for our monthly SARC newsletter and updates on clinical trials.